KYSE30 cells cotransplanting with activated CAFs significantly enhanced tumor volume (Figure 9A), increased the expression of proliferative biomarker‐Ki67, lymphangiogenic biomarker‐LYVE‐1, and microvessel biomarker‐CD31 (Figure 9B), compared with KYSE30 tumors alone. The gene discussed is LYVE1; the disease is neoplasm.